SAT0213 Low-Dose Imatinib in the Treatment of Scleroderma Pulmonary Involvement: Results of a Phase...
SAT0213 Low-Dose Imatinib in the Treatment of Scleroderma Pulmonary Involvement: Results of a Phase II Pilot Study
About this item
Full title
Author / Creator
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
More information
Scope and Contents
Contents
Background Pulmonary involvement represents a major cause of death of scleroderma patients. Cyclophosphamide showed a small beneficial effect in RCTs. There is a rational for the use of tyrosine kinase inhibitors as potential therapy for systemic sclerosis (SSc) and other fibrosing disorders. Preliminary published clinical trials are inconclusive a...
Alternative Titles
Full title
SAT0213 Low-Dose Imatinib in the Treatment of Scleroderma Pulmonary Involvement: Results of a Phase II Pilot Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1777913554
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1777913554
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2013-eular.1939
